CN1203876C - Medicine for curing postpartum subinvolution of uterus and its preparation method - Google Patents
Medicine for curing postpartum subinvolution of uterus and its preparation method Download PDFInfo
- Publication number
- CN1203876C CN1203876C CN 02104047 CN02104047A CN1203876C CN 1203876 C CN1203876 C CN 1203876C CN 02104047 CN02104047 CN 02104047 CN 02104047 A CN02104047 A CN 02104047A CN 1203876 C CN1203876 C CN 1203876C
- Authority
- CN
- China
- Prior art keywords
- medicine
- portions
- corii asini
- colla corii
- parch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 210000004291 uterus Anatomy 0.000 title description 18
- 229940079593 drug Drugs 0.000 title description 7
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241000212941 Glehnia Species 0.000 claims abstract description 5
- 241000951473 Schizonepeta Species 0.000 claims abstract description 5
- 108010052008 colla corii asini Proteins 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 208000016599 Uterine disease Diseases 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000233948 Typha Species 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 208000024891 symptom Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 229940088597 hormone Drugs 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 230000036592 analgesia Effects 0.000 abstract description 4
- 230000023597 hemostasis Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract description 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 206010036423 Postpartum uterine subinvolution Diseases 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 241000207901 Cuscuta Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000001398 Typha domingensis Species 0.000 abstract 1
- 230000001133 acceleration Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000013948 uterine smooth muscle contraction Effects 0.000 abstract 1
- 210000001015 abdomen Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 208000008454 Hyperhidrosis Diseases 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 238000002651 drug therapy Methods 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000037315 hyperhidrosis Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- COBBNRKBTCBWQP-UHFFFAOYSA-N Graveoline Chemical compound C1=C2OCOC2=CC(C=2N(C3=CC=CC=C3C(=O)C=2)C)=C1 COBBNRKBTCBWQP-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 2
- 208000029785 Puerperal disease Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- -1 sedimentation Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003191 uterotonic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 241000207925 Leonurus Species 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- 208000000091 Maternal Death Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000009263 Sheng-Hua-Tang Substances 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000005735 Water intoxication Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000004061 pubic symphysis Anatomy 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicine for treating puerperal uterine subinvolution diseases and a preparation method of the medicine. In order to solve the problems of poor treatment effect and large side effect of the existing medicine, the medicine is prepared from raw materials with the following weight proportions: 8 to 20 portions of cuscuta seeds, 8 to 20 portions of fructus lycii, 8 to 20 portions of coastal glehnia roots, 8 to 20 portions of angelica, 5 to 15 portions of white paeony roots, 5 to 15 portions of sauted ass-hide glue, 5 to 15 portions of wolfberry bark, 8 to 20 portions of motherwort herb, 8 to 20 portions of schizonepeta spike (sauted carbon) and 8 to 20 portions of cattail pollen (sauted carbon). The medicine has the advantages of comprehensive improvement of uterine subinvolution symptoms, uterine smooth muscle contraction promotion, endogenous hormone level enhancement, inflammation resistance, analgesia, hemostasis and uterine subinvolution acceleration, and thereby, the medicine is also beneficial to the shape restoration of puerperal women.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of gynaecopathia, particularly relating to a kind of is the medicine of the treatment postpartum subinvolution of uterus disease of feedstock production with the Chinese herbal medicine, the invention still further relates to the preparation method of this medicine.
Technical background:
Postpartum women through trimester of pregnancy, stages of labor phase, produce the influence in succession of Yong phase, though be human deutero-naturally physiological process because the influence of body constitution and extraneous factor, unhealthful easily with stay obstinate disease.From clinical practice, the clinical incidence rate of illness in puerperal accounts for 5.1-7.2% according to Epidemiological study, infects, hemorrhage, hypertension is maternal death three big main causes.The commonly encountered diseases kind has lochiorrhea, difficulty in defecation, spontaneous perspiration, general pain, hypogalactia, spasm syndrome, bruise etc.Wherein lochiorrhea belongs to subinvolution of uterus in the puerperal disease Chinese and western medicine, is the one of the main reasons that causes postpartum hemorrhage, adopts uterotonic treatment, the dilatation and curettage more.Even consider when bleeding profusely to hysterectomize.Untimely treatment easily causes multiple chronic diseases such as endometritis, pelvic inflammatory disease, menoxenia, and protracted course of disease is a kind of frequently-occurring disease in puerperal of serious harm WomanHealth.
To the treatment of primary disease, following clinical difficult problem puzzlement is arranged at present:
1, uterotonic such as oxytocin, ergometrine can make uterus tetanic property contraction, and effect continues a few hours, and anastalsis is arranged.But can produce side effect such as temporary serious hypertension, water intoxication, unsuitable conventional the application.
2, the employing of operative therapy such as dilatation and curettage more should be prudent, and certain indication is arranged.The antibiotics itself that postoperative must add usefulness has outside the side effect, also can influence suckling.
3, the Chinese patent medicine of present less treatment primary disease, only several not fairly obvious as effects such as motherwort formulation, SHENGHUATANG plus-minus sides, can not satisfy the clinical treatment needs.
Summary of the invention:
The object of the present invention is to provide a kind of comprehensive subinvolution of uterus symptom of improving that has, promote uterine smooth muscle to shrink, improve endogenous hormone level, antiinflammatory, analgesia, hemostasis, the quickening involution of uterus, thereby also help the medicine of the treatment postpartum subinvolution of uterus disease of postpartum women build recovery.
Another object of the present invention provides the preparation method of this medicine.
Solution of the present invention is based on motherland's medical science to pathogenetic understanding of subinvolution of uterus disease and Therapeutic Principle, with reference to modern medicinal agents, pharmaceutical research achievement and form.
The composition principle of medicine of the present invention is: in motherland's medical science, to women's warp, produce, have comparatively maturation and scientific understanding, formed the theoretical system of complete uniqueness.Think CHONG meridian being the blood pool, appoint main uterus, lochia is bloodization, and blood comes from internal organs, annotates in dashing times.If internal organs are subjected to disease, especially owing to modern women's work anxiety, the diet savoury is excessively nourished, the exhaustion due to sexual indulgence overfrequency, very easily interior volt asthenic fire, pregnant in addition cloudy blood fetus nourishing, stages of labor consumption impairment of QI Tianjin causes virtuous empty anemia in puerperal, stagnation of blood stasis, the debility of CHONG and REN meridians causes lochia, and it is dripping to produce lochia, and the vagoue pain of lumbus and abdomen, soreness of the waist and knees, Mian Se Koushi is white, the light red tongue tongue is dim, deep pulse such as counts accurately at clinical manifestation, and smelting is mended when training and is method, and kidney tonifying nourishes blood, work as blood circulation promoting and blood stasis dispelling again, blood stasis does not go, and fresh blood is had no way of with life.We form with ten flavor medicines such as Semen Cuscutae, Colla Corii Asini, Radix Angelicae Sinensis, Pollen Typhae, refine through science, be used to control the anemia of suffering from a deficiency of the kidney, the lochia that stops in the blood stasis is incomplete, promote uterine smooth muscle to shrink, improve endogenous hormone level, antiinflammatory, analgesia, hemostasis, the quickening involution of uterus, thereby also help the recovery of postpartum women build.
The medicine that the present invention treats the postpartum subinvolution of uterus disease is the medicament of being made by the following weight proportion raw material:
8～20 parts of 8～20 portions of Radix Glehniaes of 8～20 parts of Fructus Lycii of Semen Cuscutae
5～15 parts in Radix Angelicae Sinensis 5～15 parts of Colla Corii Asini of 8～20 portions of Radix Paeoniae Albas (stir-fry)
8～20 parts of Cortex Lycii 8～20 parts of Herba Schizonepetaes of 5～15 parts of Herba Leonuris (parch to black)
8～20 parts of Pollen Typhaes (parch to black)
The formula optimization weight proportion scope of medicine of the present invention is:
8～15 parts of 8～15 portions of Radix Glehniaes of 8～15 parts of Fructus Lycii of Semen Cuscutae
5～10 parts in Radix Angelicae Sinensis 5～10 parts of Colla Corii Asini of 8～15 portions of Radix Paeoniae Albas (stir-fry)
8～15 parts of Cortex Lycii 8～15 parts of Herba Schizonepetaes of 5～10 parts of Herba Leonuris (parch to black)
8～15 parts of Pollen Typhaes (parch to black)
The optimum weight proportioning of medicine of the present invention is:
10 parts of 10 portions of Radix Glehniaes of 10 parts of Fructus Lycii of Semen Cuscutae
6 parts in Radix Angelicae Sinensis 6 parts of Colla Corii Asini of 10 portions of Radix Paeoniae Albas (stir-fry)
10 parts of Cortex Lycii 10 parts of Herba Schizonepetaes of 5 parts of Herba Leonuris (parch to black)
10 parts of Pollen Typhaes (parch to black)
Said medicament is the dosage form on any pharmaceutics.
Said medicament is a granule.
The method for preparing the medicine of above-mentioned treatment postpartum subinvolution of uterus disease is to be that elder generation with behind the Colla Corii Asini stir-baked in powder of CONCHA MERETRICIS SEU CYCLINAE, is ground into 120 order fine powders; Radix Glehniae, Pollen Typhae, Semen Cuscutae, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Herba Schizonepetae discard residue with Diluted Alcohol solution reflux, extract,, and extracting solution is standby; Herba Leonuri, Fructus Lycii, Cortex Lycii decoct with water, discard residue, decoction liquor concentrates and adds 95% ethanol sedimentation, extract supernatant, merge backflow such as above-mentioned Radix Glehniae, reclaim ethanol, aqueous solution concentrates back residue drying, be ground into fine powder, make granule by described mixed after evenly with the Colla Corii Asini powder.
The concrete grammar of preparation medicine of the present invention is:
1, earlier with Colla Corii Asini with stir-baked in powder of CONCHA MERETRICIS SEU CYCLINAE after, be ground into 120 order fine powders;
2, Radix Adenophorae (Radix Glehniae), Pollen Typhae, Semen Cuscutae, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Herba Schizonepetae discard residue with Diluted Alcohol solution reflux, extract,, and extracting solution is standby;
3, Herba Leonuri, Fructus Lycii, Cortex Lycii decoct with water, and discard residue, and decoction liquor concentrates and adds 95% ethanol, sedimentation, extracts supernatant, merges extracting solution in above-mentioned 2, reclaims ethanol, and aqueous solution concentrates back residue drying, is ground into fine powder;
4, add suitable adjuvant with the Colla Corii Asini powder by the even back of described mixed and make granule with dry pressing or boiling granulation method.
An important feature of medicine of the present invention is
1, presses the Chinese medical theory prescription, and in conjunction with the pure Chinese medicinal preparation that the modern scientific research achievement is made, have short treating period clinically, the characteristics of instant effect.At commonly encountered diseases, frequently-occurring disease, a sick medicine, outstanding Chinese medicine characteristic.
2, the prescription Chinese crude drug through science extract, purification, improve active constituent content, reduce dose, confirm evident in efficacyly through pharmacodynamics, toxicological experiment, do not see toxicity.Reached purpose safe, effective, taking convenience.
3, each step of pharmaceutical preparation of the present invention all has preparation laboratory data and the support of pharmacodynamics preference data, and has formulated two content of effective testing indexs, thereby guarantees product quality.
4, treat the medicine and the medical procedure of primary disease at present, can not satisfy the clinical treatment needs.Medicine of the present invention provides a kind of new efficient medicine, increases a kind of powerful mean for clinical with the card medication.
Another important feature of medicine of the present invention is
1, contains large number of biological alkali in the medicament, comprise leonurine, stachydrine, graveoline etc., have, the contraction of uterine smooth muscle is significantly strengthened the isolated uterine excitation.
2, also contain a large amount of glycoside compositions in the medicament, comprise Quercitroside, peoniflorin and saponins, various pathogens, virus are had inhibitory action, uterine smooth muscle effect and tangible antiinflammatory action.
3, also contain a large amount of flavones ingredients in the medicament, total content reaches 1.2～2.0%, comprises ligustilide, Quercetin, rutin etc., and the isolated uterine excitation is arranged; Early pregnancy placental villi nurse tissue is cultivated, promoting sexual gland hormone-chorionic-gonadotropin hormone HCG secretory volume is increased.Also contain polysaccharide and several amino acids constituents.
The clinical use result of medicine of the present invention shows that following advantage is arranged:
1, to select natural plant for use be raw material in the present invention, and each component all meets Pharmacopoeia of the People's Republic of China regulation, press the comprehensive function of Chinese medical theory prescription and treat postpartum subinvolution of uterus disease, no chemical substance.
2, medicine of the present invention through extract, purification, active constituent content height, dose are little, and the strict quality index is arranged, and reach safe and effective, and be quality controllable, the taking convenience requirement.Meet national medical rules.
3, medicine of the present invention provides a kind of new treatment means for the postpartum subinvolution of uterus treatment for diseases, replaces Western medicine and operative therapy, avoids its side effect.And its comprehensive function treatment postpartum subinvolution of uterus disease is replenished the blank of such disease treatment.
Therefore, the medicine that the present invention treats the postpartum subinvolution of uterus disease has the comprehensive subinvolution of uterus symptom of improving, promote uterine smooth muscle to shrink, improve endogenous hormone level, antiinflammatory, analgesia, hemostasis, the quickening involution of uterus, thus the advantage that also helps the postpartum women build to recover.
For showing the effect of Drug therapy postpartum subinvolution of uterus disease of the present invention, medicine of the present invention is through the clinical observation of 90 routine systems, according to " new Chinese medicine clinical research guideline " version in 1993 draft in, the postpartum subinvolution of uterus disease patient that makes a definite diagnosis of Western medicine diagnose, dialectical standard.
Differential diagnosis in tcm standard (syndrome of yin deficiency and blood stasis)
Postpartum lochiorrhea: lochia continues more than 20 days still dripping urine endlessly.Inferior card: (1) lochia amount is many, and color is red, and is muddy or with the smelly gas that moves; (2) stomachache or lower abdomen weigh down and expand; (3) hyperhidrosis, thirsty, limbs fatigue; (4) light red tongue or purple dark spottiness; (5) moderate pulse or string are puckery.Main symptom indispensability is wherein doublely seen three of time cards, and is promptly diagnosable.
Puerperal disease main symptom: postpartum lochiorrhea, postpartum hemorrhage.Inferior card: (1) vagoue pain of lumbus and abdomen; (2) lose heart, hyperhidrosis; (3) difficulty in defecation; (4) lower abdomen tenesmus, the waistline chap.
The Western medicine diagnose standard
Subinvolution of uterus: the lochia rubra persistent period prolongs.(1) reposition of the womb: three weeks of puerperal are at the bottom of the palace still can be touched in the pubic symphysis position; (2) size, position: check that the uterus is normal big and soft, and be the retroversioflexion position; (3) pain: tenderness; (4) the soft and many palaces mouth of cervix uteri is not closed.
Instructions of taking: medicine of the present invention (trial-production of Liaoyang City's natural drug institute), the more than or postpartum hemorrhage of lochia in 21 days puerperal or promptly begin puerperal to take, each 1 bag, every day 3 times, warm boiled water.Serve on for two weeks.
The course of treatment: two weeks were a course of treatment, took two courses of treatment.Follow up a case by regular visits to two courses of treatment after the drug withdrawal.
Result of the test
(1), efficacy assessment standard and foundation: the efficacy assessment standard in the clinical research guideline of postpartum lochiorrhea " new Chinese medicine treatment " issued with reference to Ministry of Health of the People's Republic of China and drafting.
The symptom integral method
The natural law that lochia occurs: 20 days 0 minute; 22 days 2 minutes; 25 days 4 minutes; More than 30 days 6 minutes.
The late postpartum hemorrhage that subinvolution of uterus causes: 14 days puerperal is show lochia 0 minute not; Have puerperal and bleed 2 fens on a small quantity; Have on a small quantity puerperal and bleed, continue unclean 4 minutes; Amount is bled in having puerperal, continues unclean 6 minutes.
Lochia color: normal 0 minute; Dark red 1 minute; Purple 2 minutes of color; Purple dim or dark purple 3 minutes.
Lochia quality: normal 0 minute; Thick partially, but do not have clot 1 minute; Thick, a small amount of little clot 2 minutes; Thickness, volume clot 3 minutes;
Lochia abnormal smells from the patient: normal 0 minute; Light abnormal flavour 1 minute is arranged; Frowziness 2 minutes; Smelly oxious gas flavor 3 minutes are arranged.
Lower abdomen pain: painless 0 minute; Sagging distention in the smaller abdomen 1 minute; The vagoue pain of lumbus and abdomen, constant 2 minutes; Lower abdomen pain was difficult to stand 3 fens.
The hyperhidrosis of losing heart: normal 0 minute; Little sense is felt oppressed, and hands, the sufficient heart often had sweating 1 minute; Out of breath uncomfortable in chest, sweating while acting 2 minutes; Rapid breathing was from dropping sweat 3 minutes.
Difficulty in defecation: defecated normal 0 minute; Be hard and dry 1 fen; Constipation due to dry stool was difficult to resolve 2 fens; Constipation due to dry stool needs just can solve 3 fens with medicine.
Abdominal circumference: normal 0 minute; Lower abdomen projection 1 minute; Following ventral tubercle 2 minutes; Lower abdomen tenesmus 3 minutes.
Tongue fur: normal 0 minute; Body of the tongue is red partially, few Tianjin of yellow and thin fur 1 minute; The few tongue of red tongue 2 minutes; Red and uncoated tongue 3 minutes.
Efficacy assessment standard
Recovery from illness: treatment back lochia is clean, stopped bleeding, and other symptom disappears substantially, and drug withdrawal is not recurrence after 15 days, and integrated value is below 3 minutes.
Produce effects: treatment back lochia or amount of bleeding have reduced more than 1/3 before than treatment, other transference cure or alleviate, and drug withdrawal is recurrence after 15 days, and integrated value has reduced more than 2/3 before than treatment.
Effectively: treatment back lochia or amount of bleeding are improved than treatment is preceding, and also than alleviating before the treatment, drug withdrawal is not recurrence after 15 days for other symptom, and integrated value has reduced more than 1/3 before treating.
Invalid: treatment back lochia or amount of bleeding do not have and improve or increase the weight of, integrated value than treatment before no change or than reducing less than 1/3 before the treatment.
Efficacy analysis: the detailed results of this clinical observation, see the following table general curative effect for details
Group n recovery from illness produce effects enabledisable
Observation group's 90 examples, 48 examples (53.33%) 21 example (23.33%) 15 example (16.67%) 6 example (6.67%)
As can be seen from the above table: the cure rate of Drug therapy subinvolution of uterus of the present invention reaches 55.33%, obvious effective rate 23.33%, effective percentage 16.67%, inefficiency 6.67%, total obvious effective rate 76.67%, total effective rate 93.33%.
The curative effect of state of an illness integration relatively before and after the treatment
Before the group n treatment (x ± s) treat afterwards (x ± s)
Observation group's 90 examples 15.07 ± 4.04 15.07 ± 4.04
※ ※
Annotate: with relatively use before the treatment
※ ※Expression P＜0.01.
As can be seen from the above table: the curative effect of state of an illness integration relatively has utmost point significant difference, P＜0.01 before and after the treatment of Drug therapy subinvolution of uterus of the present invention.
The curative effect that symptom and sign changes before and after the treatment relatively
From following table as can be seen: the curative effect that symptom and sign changes before and after the treatment of Drug therapy subinvolution of uterus of the present invention relatively has utmost point significant difference, P＜0.01.
After treating before the treatment
Sign n u p
+++ ++ + - +++ ++ + -
Lochia color 90 examples 0 18 45 27 00 15 75 3.8013＜0.01
Lochia quality 90 examples 30 48 12 003 21 66 6.3206＜0.01
Lochia abnormal smells from the patient 90 examples 18 36 33 309 24 57 4.8970＜0.01
Lower abdomen pain 90 examples 9 18 57 600 18 72 4.8970＜0.01
Hyperhidrosis 90 examples 16 27 45 203 21 66 6.3206＜0.01 of losing heart
Difficulty in defecation 90 examples 06 57 27 03 15 72 3.2870＜0.01
Abdominal circumference 90 examples 18 25 35 12 09 15 66 4.1442＜0.01
Tongue fur 90 examples 0 27 48 15 066 78 4.9044＜0.01
1, the comparison of the state of an illness and curative effect
State of an illness n recovery from illness produce effects enabledisable x
2p
Light 15 examples 15 000
In 69 examples 33 21 15 0 8.5217＜0.05
Weigh 6 examples 0006
As can be seen from the above table: the state of an illness and curative effect compare before and after the treatment of Drug therapy subinvolution of uterus of the present invention, x
2=8.5217, there is significant difference p＜0.05.
Model case: Wang, woman, 25 years old, workman, No. 9, case numbering.
This patient is in primiparity in October, 2,000 one girl baby, and 27 days puerperal, lochia was more than, and color is purple dark, and clot is arranged, sagging distention in the smaller abdomen, pain, the hyperhidrosis of breathing hard, red tongue, few tongue, thready and rapid pulse.Blood, routine urinalysis, electrocardiogram, liver, renal function procuratorial work are normal.Through with 1 bag of medicine of the present invention a time, 2 times on the one, lochia was promptly ended on 5th, and other symptom has improvement, continues to take to the course of treatment and finishes, and the light gas of conscious body is refreshing, and build recovers, and simultaneous phenomenon all disappears, electrocardiogram, and liver, renal function are examined all normal again, clinical cure.Do not find untoward reaction during the medication.
The clinical efficacy of medicine of the present invention
Test statistics shows: the clinical efficacy of Drug therapy subinvolution of uterus patient 90 examples of the present invention is satisfied, its cure rate reaches 53.33% (48/90), and obvious effective rate reaches 23.33% (21/90), and effective percentage reaches 16.67% (15/90), cure-remarkable-effectiveness rate reaches 76.67%, and total effective rate reaches 93.33%.
Embodiment
Take by weighing raw material by following proportioning
Semen Cuscutae 8,10,20kg Fructus Lycii 8,10,20kg Radix Glehniae 8,10,20kg
Radix Angelicae Sinensis 8,10, the 20kg Radix Paeoniae Alba 5,6,15kg Colla Corii Asini (stir-fry) 5,6,15kg
Cortex Lycii 5,5,15kg Herba Leonuri 8,10,20kg Herba Schizonepetae (parch to black) 8,10,20kg
Pollen Typhae (parch to black) 8,10,20kg
Production method is as follows;
Earlier with Colla Corii Asini with stir-baked in powder of CONCHA MERETRICIS SEU CYCLINAE after, be ground into 120 order fine powders; Radix Adenophorae (Radix Glehniae), Pollen Typhae, Semen Cuscutae, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Herba Schizonepetae discard residue with Diluted Alcohol solution reflux, extract,, and extracting solution is standby; Herba Leonuri, Fructus Lycii, Cortex Lycii decoct with water, and discard residue, and decoction liquor concentrates and adds 95% ethanol, sedimentation, extracts supernatant, merges reflux extracting liquid, reclaims ethanol, and aqueous solution concentrates back residue drying, is ground into fine powder; Make granule with the adjuvant that it is suitable that the Colla Corii Asini powder mixes in proportion the back adding with dry pressing or boiling granulation method.
Claims (5)
1, a kind of medicine for the treatment of the postpartum subinvolution of uterus disease is characterized in that making pharmaceutical composition by the following weight proportion raw material:
Semen Cuscutae 8-20 part Fructus Lycii 8-20 part Radix Glehniae 8-20 part
Radix Angelicae Sinensis 8-20 part Radix Paeoniae Alba 5-15 part Colla Corii Asini 5-15 part
Cortex Lycii 5-15 part Herba Leonuri 8-20 part Herba Schizonepetae 8-20 part
Pollen Typhae 8-20 part;
Described Colla Corii Asini is for frying Colla Corii Asini, and Herba Schizonepetae is the parch to black Herba Schizonepetae, and Pollen Typhae is the parch to black Pollen Typhae.
2, the medicine of treatment postpartum subinvolution of uterus disease according to claim 1 is characterized in that the weight proportion of described raw material is:
Semen Cuscutae 8-15 part Fructus Lycii 8-15 part Radix Glehniae 8-15 part
Radix Angelicae Sinensis 8-15 part Radix Paeoniae Alba 5-10 part Colla Corii Asini 5-10 part
Cortex Lycii 5-10 part Herba Leonuri 8-15 part Herba Schizonepetae 8-15 part
Pollen Typhae 8-15 part;
Described Colla Corii Asini is for frying Colla Corii Asini, and Herba Schizonepetae is the parch to black Herba Schizonepetae, and Pollen Typhae is the parch to black Pollen Typhae.
3, the medicine of treatment postpartum subinvolution of uterus disease according to claim 2 is characterized in that the weight proportion of described raw material is:
10 parts of 10 portions of Radix Glehniaes of 10 parts of Fructus Lycii of Semen Cuscutae
6 parts in 6 parts of Colla Corii Asini of 10 portions of Radix Paeoniae Albas of Radix Angelicae Sinensis
10 parts of 10 parts of Herba Schizonepetaes of 5 parts of Herba Leonuris of Cortex Lycii
10 parts of Pollen Typhaes;
Described Colla Corii Asini is for frying Colla Corii Asini, and Herba Schizonepetae is the parch to black Herba Schizonepetae, and Pollen Typhae is the parch to black Pollen Typhae.
4, according to the medicine of claim 1,2 or 3 described treatment postpartum subinvolution of uterus diseases, the dosage form that it is characterized in that this medicine is a granule.
5, a kind of method for preparing treatment postpartum subinvolution of uterus disease medicine is characterized in that: earlier with Colla Corii Asini with stir-baked in powder of CONCHA MERETRICIS SEU CYCLINAE after, be ground into 120 order fine powders; Radix Glehniae, parch to black Herba Schizonepetae, parch to black Pollen Typhae, Semen Cuscutae, Radix Angelicae Sinensis, the Radix Paeoniae Alba are used the alcoholic solution reflux, extract,, discard residue, and extracting solution is standby; Herba Leonuri, structure Fructus Lycii, Cortex Lycii decoct with water, and discard residue, and decoction liquor concentrates and adds 95% ethanol sedimentation, extracts supernatant; Merge supernatant and reflux extracting liquid, reclaim ethanol; Aqueous solution is concentrated back residue drying, be ground into fine powder; With make granule behind the Colla Corii Asini powder mix homogeneously; The weight proportion of above-mentioned various raw materials is:
Semen Cuscutae 8-20 part Fructus Lycii 8-20 part Radix Glehniae 8-20 part
Radix Angelicae Sinensis 8-20 part Radix Paeoniae Alba 5-15 part Colla Corii Asini 5-15 part
Cortex Lycii 5-15 part Herba Leonuri 8-20 part Herba Schizonepetae 8-20 part
Pollen Typhae 8-20 part,
Described Colla Corii Asini is for frying Colla Corii Asini, and Herba Schizonepetae is the parch to black Herba Schizonepetae, and Pollen Typhae is the parch to black Pollen Typhae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02104047 CN1203876C (en) | 2002-03-07 | 2002-03-07 | Medicine for curing postpartum subinvolution of uterus and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02104047 CN1203876C (en) | 2002-03-07 | 2002-03-07 | Medicine for curing postpartum subinvolution of uterus and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1443546A CN1443546A (en) | 2003-09-24 |
| CN1203876C true CN1203876C (en) | 2005-06-01 |
Family
ID=27810793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02104047 Expired - Fee Related CN1203876C (en) | 2002-03-07 | 2002-03-07 | Medicine for curing postpartum subinvolution of uterus and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1203876C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2403019C1 (en) * | 2009-09-17 | 2010-11-10 | Фарук Ахмадулович Сунагатуллин | Method for prevention of postnatal subinvolution of uterus in cows |
| CN102379913B (en) * | 2011-10-26 | 2013-10-02 | 吉泰安（四川）药业有限公司 | Pharmaceutical composition for treating subinvolution of uterus, and preparation method and use thereof |
| CN105248763A (en) * | 2015-10-22 | 2016-01-20 | 上海裕家农业科技发展有限公司 | Uterine contraction drink |
| CN105343784A (en) * | 2015-12-02 | 2016-02-24 | 杨慧丽 | Traditional Chinese medicine decoction for treating puerperal subinvolution of uterus |
| CN106924459A (en) * | 2015-12-29 | 2017-07-07 | 印骏 | A kind of herbal composite and its preparation method for woman postpartum disease conditioning |
-
2002
- 2002-03-07 CN CN 02104047 patent/CN1203876C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1443546A (en) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1650923A (en) | Medicinal composition for treating theumalism and rheumatism diseases | |
| CN106110291A (en) | A kind of nutritional preparation for kidney cell reparation and preparation method thereof | |
| CN1203876C (en) | Medicine for curing postpartum subinvolution of uterus and its preparation method | |
| CN102430076A (en) | Navel-applying weight-losing powder | |
| CN1287830C (en) | Chinese traditional medicine compound preparation for treating gynecopathy and preparation method thereof | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN102688361A (en) | Traditional Chinese medicinal composition for treating dysmenorrhoea and preparation thereof | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN1628771A (en) | Lotion for treating gynecological disease and its preparation process | |
| CN1240412C (en) | Chinese medicine compound preparation for treating piles and preparing process thereof | |
| CN1148217C (en) | Chinese medicine for treating chronic bronchitis | |
| CN1253196C (en) | Medicine for treating colitis | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN1724022A (en) | Traditional Chinese medicine compound preparation for preventing and treating abnormal uterine bleeding and its production method | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN101028372A (en) | Chinese medicinal decoction for treating hives | |
| CN1176689C (en) | Medicine for treating primary dysmenorrhea and its prepn | |
| CN1199677C (en) | Medicine for treating piles | |
| CN1628770A (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN1205947C (en) | Chinese medicine prepn for treating hepatocirrhosis and liver ascites | |
| CN104257779B (en) | Gout-resisting pharmaceutical composition and preparation method of gout-resisting pharmaceutical composition | |
| CN1739678A (en) | Medicine for treating pain caused by wind, cold and wetness evils and its prepn | |
| CN1299748C (en) | Fat reducing regulating Qi supplement bag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050601 Termination date: 20110307 |